Healthcare Services

Neurology Clinical Trials Market Insights Exploring Expansion Opportunities Through 2030

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Neurology Clinical Trials Market Over The Forecast Period?

The neurology clinical trials market size has experienced significant growth in recent years. It is anticipated to increase from $5.8 billion in 2025 to $6.21 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by several factors, including a rise in the prevalence of neurological diseases, the enlargement of pharmaceutical research pipelines, heightened investment in neurology drug development, the availability of sophisticated imaging tools, and an uptick in participation in clinical research.

The neurology clinical trials market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach a value of $8.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors driving this growth during the forecast period include the increasing adoption of AI-driven trial analytics, a heightened demand for more rapid trial execution, the broadening of patient-centric trial models, greater integration of remote monitoring technologies, and an amplified focus on rare neurological conditions. Key trends anticipated in the forecast period encompass a rising embrace of adaptive clinical trial designs, the increased utilization of digital patient monitoring tools, an evolving emphasis on biomarker-based neurology trials, the expansion of decentralized clinical trial models, and a stronger focus on generating real-world evidence.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25847&type=smp

Which Growth Drivers Are Expected To Support The Neurology Clinical Trials Market Forward?

The increasing incidence of neurological disorders is projected to drive the expansion of the neurology clinical trials market. Neurological disorders are defined as conditions impacting the brain, spinal cord, or nerves, thereby disrupting the nervous system’s normal functioning. The rise in these disorders is primarily linked to an aging demographic, as older individuals are more susceptible to age-related conditions like Alzheimer’s and Parkinson’s disease. Neurology clinical trials play a vital role in tackling neurological disorders by assessing new treatments, drugs, or interventions to improve diagnostic methods, control symptoms, slow disease advancement, and enhance patient outcomes. For instance, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, stated that the number of Australians affected by dementia is anticipated to more than double, climbing from 411,100 in 2023 to 849,300 by 2058. Additionally, by 2058, roughly 315,500 men and 533,800 women are expected to be living with dementia. Therefore, the growing prevalence of neurological disorders is a key factor propelling the growth of the neurology clinical trials market.

Which Segment-Based Categories Are Covered In The Neurology Clinical Trials Market?

The neurology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Other Indications

4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users

Subsegments:

1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies

2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification

3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis

4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment

What Trends Are Influencing The Neurology Clinical Trials Market?

Major companies operating in the neurological disorder diagnostics market are prioritizing the development of innovative solutions, such as neurological disease quantification software, to assist one billion individuals affected by neurological diseases worldwide. Neurological disease quantification software serves as a tool for measuring and analyzing brain function and the advancement of disease in neurological conditions. As an illustration, in January 2024, Quibim, a Spain-based biotechnology company, launched QP-Brain, an AI-based early-stage neurological disease quantification software. QP-Brain by Quibim is advanced neuroimaging analysis software specifically designed to quantify brain tissue alterations in neurological diseases. Its distinct capabilities include AI-powered automated segmentation and detailed volumetric analysis, providing precise insights into brain structure changes for both clinical and research applications.

Which Organizations Are Involved In The Neurology Clinical Trials Market?

Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.

Access The Complete Neurology Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/neurology-clinical-trials-global-market-report

Which Area Represents The Largest Portion Of The Neurology Clinical Trials Market?

North America was the largest region in the neurology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurology Clinical Trials Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=25847&type=smp

Browse Through More Reports Similar to the Global Neurology Clinical Trials Market 2026, By The Business Research Company

Interventional Neurology Devices And Equipment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neuroprosthetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuroscience Antibodies And Assays Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuroscience-antibodies-and-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795